• CID-078 is a first-in-class oral macrocycle that drives synthetic lethality in a wide range of cancers
• Circle expects to initiate clinical studies in 2024

SAN FRANCISCO–(BUSINESS WIRE)–July 19, 2023–

Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the selection of CID-078 for its first clinical development program. CID-078 is the first-and-only-in-class dual inhibitor of Cyclins A and B,…